Crizotinib treatment for advanced non-small-cell lung cancer patients: a budget impact analysis based in Thailand
© 2017 Informa UK Limited, trading as Taylor & Francis Group. Objective: With the advent of the anaplastic lymphoma kinase (ALK) inhibitor, treatment of ALK-positive advanced non-small-cell lung cancer (NSCLC) patients has become more effective while drug costs are still a major concern. This...
Saved in:
Main Authors: | , |
---|---|
Format: | Journal |
Published: |
2018
|
Subjects: | |
Online Access: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85015768144&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/57704 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Chiang Mai University |